Campbell & CO Investment Adviser LLC Makes New Investment in TransMedics Group, Inc. $TMDX

Campbell & CO Investment Adviser LLC purchased a new stake in shares of TransMedics Group, Inc. (NASDAQ:TMDX) in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm purchased 14,231 shares of the company’s stock, valued at approximately $1,597,000.

A number of other hedge funds also recently modified their holdings of the business. Nordea Investment Management AB bought a new stake in shares of TransMedics Group in the third quarter worth $4,070,000. First Horizon Corp acquired a new position in TransMedics Group during the 3rd quarter worth about $43,000. New York State Teachers Retirement System lifted its holdings in TransMedics Group by 4.2% during the 3rd quarter. New York State Teachers Retirement System now owns 28,803 shares of the company’s stock worth $3,232,000 after buying an additional 1,165 shares during the period. Peregrine Capital Management LLC grew its position in shares of TransMedics Group by 16.5% in the 3rd quarter. Peregrine Capital Management LLC now owns 68,406 shares of the company’s stock valued at $7,675,000 after buying an additional 9,676 shares during the last quarter. Finally, Benjamin Edwards Inc. acquired a new stake in shares of TransMedics Group in the third quarter valued at about $335,000. Institutional investors and hedge funds own 99.67% of the company’s stock.

Insider Activity at TransMedics Group

In other news, CFO Gerardo Hernandez sold 920 shares of the stock in a transaction dated Thursday, December 4th. The shares were sold at an average price of $139.62, for a total transaction of $128,450.40. Following the transaction, the chief financial officer owned 15,064 shares of the company’s stock, valued at $2,103,235.68. This represents a 5.76% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Anil P. Ranganath sold 3,000 shares of the firm’s stock in a transaction dated Tuesday, November 25th. The shares were sold at an average price of $145.22, for a total value of $435,660.00. Following the completion of the sale, the insider owned 13,955 shares of the company’s stock, valued at approximately $2,026,545.10. This represents a 17.69% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 13,062 shares of company stock worth $1,797,634 over the last three months. 7.00% of the stock is currently owned by company insiders.

TransMedics Group Price Performance

Shares of TMDX opened at $143.37 on Friday. The firm has a market cap of $4.90 billion, a PE ratio of 58.04 and a beta of 2.03. TransMedics Group, Inc. has a 52-week low of $55.00 and a 52-week high of $156.00. The business’s 50 day moving average price is $130.87 and its two-hundred day moving average price is $122.58. The company has a debt-to-equity ratio of 1.43, a quick ratio of 7.13 and a current ratio of 7.69.

TransMedics Group (NASDAQ:TMDX) last released its quarterly earnings data on Wednesday, October 29th. The company reported $0.66 earnings per share for the quarter, beating the consensus estimate of $0.37 by $0.29. The company had revenue of $143.82 million during the quarter, compared to analyst estimates of $145.33 million. TransMedics Group had a net margin of 16.20% and a return on equity of 31.42%. TransMedics Group’s revenue for the quarter was up 32.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.12 EPS. On average, equities analysts anticipate that TransMedics Group, Inc. will post 1 EPS for the current year.

Wall Street Analyst Weigh In

TMDX has been the topic of a number of recent analyst reports. Zacks Research lowered TransMedics Group from a “strong-buy” rating to a “hold” rating in a research note on Monday, October 6th. Weiss Ratings restated a “hold (c)” rating on shares of TransMedics Group in a report on Wednesday, October 8th. Piper Sandler restated an “overweight” rating on shares of TransMedics Group in a research report on Monday, December 22nd. Jefferies Financial Group began coverage on shares of TransMedics Group in a research report on Monday, October 13th. They set a “buy” rating and a $145.00 price objective for the company. Finally, Needham & Company LLC lifted their target price on shares of TransMedics Group from $148.00 to $166.00 and gave the stock a “buy” rating in a research note on Monday, December 8th. Six investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $144.25.

About TransMedics Group

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.